Tumors Manufacturers, Suppliers & Companies (Medical Specialties)
-
Manufacturerbased in Malmö, SWEDEN
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Oncoral is a novel oral irinotecan tablet in ...
Oncoral - Novel Daily Irinotecan Chemotherapy Agent
Oncoral is a novel daily irinotecan chemotherapy in development. Irinotecan chemotherapy has an established potent anti-tumor effect – even in difficult to treat cancers. Oncoral is a daily irinotecan tablet with the potential to offer better ...
CONTACT SUPPLIER -
Manufacturerbased in Santiago de Compostela, SPAIN
We develop and commercialize new chemical tools to spread the use of fluorescence-based methods in drug discovery. Celtarys is a newly created company focused on the development of innovative chemical tools that improve the efficiency of the High ...
-
Manufacturerbased in St Paul, MINNESOTA (USA)
Quench Medical is developing a novel aerosol platform technology to deliver medicine into deep areas of the lung with unprecedented efficiency to greatly increase efficacy in treating pulmonary airway diseases. The primary application of this ...
Quench - Aerosol Platform Technology
Quench Medical's aerosol platform technology is designed to deliver medicine into deep areas of the lung with unprecedented efficiency to greatly increase efficacy in treating pulmonary airway diseases. ...
CONTACT SUPPLIER -
Manufacturerbased in Emeryville, CALIFORNIA (USA)
Gritstone is developing targeted immunotherapies for cancer and infectious disease. Gritstone’s approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells ...
Gritstone - Model EDGE - Cancer Cell Therapies
We are leveraging EDGE to define targets for T-cell receptor (TCR) directed cell therapies. These additional targets that were identified and validated by Gritstone EDGE™ enable us to partner with others or develop additional therapeutic ...
CONTACT SUPPLIER -
Manufacturerbased in Gaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
AIM - ACT Adoptive Cellular Therapy
NexImmune’s AIM™ platform is the foundation for our unique approach to immunotherapy. Our AIM nanoparticle technology enables the development of immunotherapies that orchestrate specific T cell function and trigger a precise immune ...
CONTACT SUPPLIER -
Technologybased in Wichita, KANSAS (USA)
Neotherma Oncology is led by experienced healthcare executives who are working toward the dream of more effective treatments for cancer. NeoTherma Oncology is developing a groundbreaking type of radio frequency (RF) thermal treatment for deep solid ...
NeoTherma VectRx - Clinical Stage Medical Device
NeoTherma Oncology is a clinical stage medical device company developing a proprietary Thermal Treatment (VectRx) system for deep solid tumors. Our technology is based on applying a safe, non-invasive, non-ionizing electromagnetic field to produce ...
CONTACT SUPPLIER -
Manufacturerbased in Durham, NORTH CAROLINA (USA)
GeneCentric Therapeutics is applying our proprietary rT(I)ME Explorer Platform to identify high resolution molecular subtypes and drug responder populations that enable the development of precision cancer drugs while improving patient outcomes. Our ...
GeneCentric - Pancreatic Cancer Subtype Profiler (PurIST)
Pancreatic Cancer is the 11th most common cancer type with an estimated 55,000 new cases in the US in 2018, according to the United States National Cancer Institute. While it represents three percent of all cancers, pancreatic cancer is one of the ...
CONTACT SUPPLIER -
Manufacturerbased in Brisbane, CALIFORNIA (USA)
Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer. Our lead therapy is AO-176, an anti-CD47 antibody ...
Arch - Model AO-176 - Antibody for Cancer
We are advancing our pipeline of antibodies for the treatment of patients with cancer. AO-176 is a highly differentiated anti-CD47 IgG2 antibody currently in clinical trials for solid tumors and multiple myeloma. AO-176 works by blocking the ...
CONTACT SUPPLIER -
Manufacturerbased in Richland, WASHINGTON (USA)
Isoray is an innovative company that designs and develops state-of-the-art, personalized brachytherapy products that provide a more cost-effective cancer treatment. Isoray employs approximately 40 employees, dedicated to the introduction of a unique ...
-
Manufacturerbased in Oxford, UNITED KINGDOM
Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Professor Shisong Jiang – Recombinant Overlapping Peptides (ROP). These ...
Oxford - Recombinant Overlapping Peptide
Tumours can often avoid being targeted by these T Cells by looking like a cell found normally in the body often referred to as “self”. If a group of T Cells can be encouraged to recognise these tumours as foreign and not self then they ...
CONTACT SUPPLIER -
Manufacturerbased in Abingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
PsiOxus - Model NG-796A - Single or Multi-Protein Therapeutics Medicine
Three transgenes: Producing IL-12, IL-15 and a chemokine. As part of our expanding T-SIGn platform pipeline, this candidate is progressing through its IND enabling activities in readiness for entering clinical ...
CONTACT SUPPLIER -
Manufacturerbased in Buffalo, NEW YORK (USA)
POP Biotechnologies, Inc. (POP BIO) is dedicated to addressing critical medical challenges with advanced nanotechnologies. POP BIO’s key breakthrough, the porphyrin-phospholipid (PoP) platform, facilitates the creation of powerful light-targeted ...
Effective Anti-tumor Treatment Services
Nanograms of peptide reverse established and metastatic tumor rowth in TC-1 tumor model. Other cancer models show synergy with checkpoint blockade inhibition and other anti-tumor treatments. ...
CONTACT SUPPLIER -
Service providerbased in Morrisville, NORTH CAROLINA (USA)
Istari Oncology, Inc., is a clinical-stage biotechnology company developing innovative immunotherapies for the treatment of patients with solid tumors. Istari has built a passionate and experienced leadership team focused on clinical trial strategy ...
Innovative Immunotherapies for the Treatment
The tumor environment contains all the ingredients needed to mount an anticancer immune response—tumor antigens, antigen presenting cells (APCs, including tumor-associated macrophages [TAMs] and dendritic cells), and T cells—but ...
CONTACT SUPPLIER -
Technologybased in South San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
Sutro - iADCs and Antibody-Drug Conjugates
Sutro’s cell-free expression technology provides a rapid and powerful platform for the discovery and development of next generation antibody-drug conjugates ...
CONTACT SUPPLIER -
Technologybased in München, GERMANY
We are an interdisciplinary team with a focus on research, translation, clinical development, manufacturing, and commercialization. Our passionate team is committed to provide safe and effective tumor therapy. We are supported by a strong scientific ...
FUSIX Technology
The FUSIX Technology relies on a fusion-based oncolytic virus platform. Below you can see FUB101 in action. In this timelapse video FUB101 is killing a monolayer of cancer cells (HCC) within 48 hours through a fusogenic mechanism of action. ...
CONTACT SUPPLIER -
Technologybased in Schlieren, SWITZERLAND
We want to empower people to deal with their malignant cells through their own immune system just like we deal with viral infections. Today’s cancer immunotherapies are powerful but, to the detriment of their effect, not very tumor-selective. ...
Antibody Therapies
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. ...
CONTACT SUPPLIER -
Manufacturerbased in New Haven, CONNECTICUT (USA)
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology. We are focused on utilizing cutting-edge ...
BioXcel - Model BXCL701 - Immuno-Oncology Medicine
BXCL701 (talabostat) is an investigational, oral small molecule inhibitor of dipeptidyl peptidases (DPP)—primarily DPP 8/9 and DPP 4—which triggers inflammasome to alert and prime immune cells, leading to induction of IL-18 and ...
CONTACT SUPPLIER -
Manufacturerbased in Seattle, WASHINGTON (USA)
SEngine Precision Medicine empowers patients and oncologists with more informed treatment options. SEngine's high-throughput technology simultaneously tests more than 200 cancer drugs against a patient's unique tumor organoid outside the body. The ...
-
Manufacturerbased in Boston, MASSACHUSETTS (USA)
We harness the natural power of the lymph nodes to generate enhanced immune responses against tumors. Our science is defining the future of immunotherapy, with the goal of giving patients who are battling cancer their best possible outcome. We’re ...
Elicio - Model ELI-008 - Multivalent Lymph Node–Targeted AMP Peptide Vaccine
ELI-008 is a multivalent lymph node–targeted AMP peptide vaccine developed to target p53 hotspot mutations. p53 is a tumor-suppressing protein that controls the cell cycle, DNA replication, and uncontrolled cell division during ...
CONTACT SUPPLIER -
Technologybased in Paris, FRANCE
The mission of Alderaan Biotechnology is to develop novel therapies to treat cancer by targeting cells from the immune system. Alderaan Biotechnology programs are related to the elimination of Regulatory T cells and to the hyper activation of ...
Model CD160TM - Natural Killer Cells
CD160TM NK cell boost using CD160-TM specific monoclonal antibodies. Natural Killer cells (NK) represents a cell population involved in the cancer cell destruction through recognition of tumor cells followed by cell killing through cell-cell contact ...
CONTACT SUPPLIER
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you